Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 13/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20418605 | 1.00 | STAT3 (0.50) | STAT3FFAR4SGMS2PTPN2PTPN1 | |
| SCHEMBL20418435 | 0.93 | STAT3 (0.43) | STAT3SGMS2MEN1KMT2A | |
| SCHEMBL29447476 | 0.93 | STAT3 (0.43) | STAT3SGMS2MEN1KMT2A | |
| SCHEMBL20400950 | 0.92 | STAT3 (0.48) | STAT3SGMS2 | |
| SCHEMBL28431174 | 0.89 | STAT3 (0.41) | STAT3FFAR4SGMS2PRMT5MEN1 | |
| SCHEMBL28436257 | 0.89 | STAT3 (0.48) | STAT3 | |
| SCHEMBL20418612 | 0.85 | STAT3 (0.49) | STAT3PRMT5 | |
| SCHEMBL29447664 | 0.85 | STAT3 (0.49) | STAT3PRMT5 | |
| SCHEMBL29447631 | 0.83 | STAT3 (0.41) | STAT3SGMS2MEN1ALDH1A1KMT2A | |
| SCHEMBL28439969 | 0.83 | STAT3 (0.42) | STAT3SGMS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11299480-B2 | 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors | UNIVERSITY OF HAWAII (US) | 2022-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299480-B2 | 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors | STAT3, JAK2, STAT5A | STAT3 1/4885FFAR4 3288/4885SGMS2 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.